S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
Log in
NYSE:MRK

Merck & Co., Inc. Stock Forecast, Price & News

$80.25
-0.90 (-1.11 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$80.13
Now: $80.25
$81.15
50-Day Range
$79.29
MA: $81.77
$85.00
52-Week Range
$65.25
Now: $80.25
$89.20
Volume6.20 million shs
Average Volume9.72 million shs
Market Capitalization$203.04 billion
P/E Ratio17.75
Dividend Yield3.20%
Beta0.43
Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases; neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. It provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat non-small-cell lung, ovarian and breast, esophageal, thyroid, cervical, and brain cancers; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. In addition, the company offers drugs for hepatocellular and merkel cell carcinoma; antibiotic and anti-inflammatory drugs for infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, bovine, and swine; vaccines for poultry; parasiticides for sea lice in salmon; and antibiotics and vaccines for fish. Further, it provides companion animal products; diabetes mellitus treatment and anthelmintic products for dogs and cats; products to treat fleas, ticks, mosquitoes, and sandflies; horse fertility management products for swine; and dog, cat, and horse vaccines. Additionally, the company offers services and solutions that focus on engagement, clinical, and health analytics. Merck & Co., Inc. has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Almac Discovery Ltd.; Skyhawk Therapeutics, Inc.; Ridgeback Biotherapeutics; Shanghai Junshi Biosciences Co., Ltd.; FUJIFILM Corporation; Intec Pharma Ltd.; Transcenta Holding Ltd.; and Janux Therapeutics, Inc. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers; and physicians and physician distributors, veterinarians, and animal producers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Merck & Co., Inc. logo

MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

24th out of 1,925 stocks

Pharmaceutical Preparations Industry

10th out of 773 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP58933Y10
Phone908-740-4000
Employees71,000
Year Founded1891

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.84 billion
Cash Flow$6.52 per share
Book Value$10.21 per share

Profitability

Net Income$9.84 billion

Miscellaneous

Outstanding Shares2,530,034,000
Market Cap$203.04 billion
Next Earnings Date2/4/2021 (Confirmed)
OptionableOptionable
$80.25
-0.90 (-1.11 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

How has Merck & Co., Inc.'s stock been impacted by COVID-19 (Coronavirus)?

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has increased by 1.3% and is now trading at $80.25.
View which stocks have been most impacted by COVID-19
.

Is Merck & Co., Inc. a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Merck & Co., Inc. stock.
View analyst ratings for Merck & Co., Inc.
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Merck & Co., Inc.?

Wall Street analysts have given Merck & Co., Inc. a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Merck & Co., Inc. wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. CEO Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among Merck & Co., Inc.'s employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Merck & Co., Inc.'s next earnings date?

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Merck & Co., Inc.
.

How can I listen to Merck & Co., Inc.'s earnings call?

Merck & Co., Inc. will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings data on Tuesday, October, 27th. The company reported $1.74 EPS for the quarter, beating the consensus estimate of $1.44 by $0.30. The business had revenue of $12.55 billion for the quarter, compared to analyst estimates of $12.21 billion. Merck & Co., Inc. had a net margin of 24.33% and a trailing twelve-month return on equity of 53.83%. The business's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the business earned $1.51 EPS.
View Merck & Co., Inc.'s earnings history
.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, November 17th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.65 per share on Friday, January 8th. This represents a $2.60 dividend on an annualized basis and a dividend yield of 3.24%. The ex-dividend date is Monday, December 14th. This is a positive change from Merck & Co., Inc.'s previous quarterly dividend of $0.61.
View Merck & Co., Inc.'s dividend history
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. pays an annual dividend of $2.60 per share and currently has a dividend yield of 3.20%. Merck & Co., Inc. does not yet have a strock track record of dividend growth. The dividend payout ratio of Merck & Co., Inc. is 50.10%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 42.83% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.
View Merck & Co., Inc.'s dividend history.

What price target have analysts set for MRK?

14 brokers have issued twelve-month target prices for Merck & Co., Inc.'s stock. Their forecasts range from $88.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s share price to reach $95.36 in the next twelve months. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Merck & Co., Inc.
or view Wall Street analyst' top-rated stocks.

Who are some of Merck & Co., Inc.'s key competitors?

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), The Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and The Home Depot (HD).

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the following people:
  • Mr. Kenneth C. Frazier, Chairman, Pres & CEO (Age 66, Pay $6.64M)
  • Mr. Robert M. Davis, Exec. VP of Global Services & CFO (Age 54, Pay $3.29M)
  • Ms. Jennifer L. Zachary, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $2.47M)
  • Mr. Sanat Chattopadhyay, Exec. VP & Pres of Merck Manufacturing Division (Age 61, Pay $2.01M)
  • Mr. David Michael Williams, Chief Information & Digital Officer
  • Mr. Peter Dannenbaum CFA, VP of Investor Relations
  • Michael W. Fleming, Sr. VP and Chief Ethics & Compliance Officer (Age 62)
  • Ms. Jennifer Mauer, VP of Global Communications
  • Mr. Michael T. Nally, Chief Marketing Officer & Exec. VP (Age 45)
  • Mr. Steven C. Mizell, Exec. VP & Chief HR Officer (Age 61)

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.14%), New York State Teachers Retirement System (0.14%), Alecta Pensionsforsakring Omsesidigt (0.12%), Sarasin & Partners LLP (0.10%), Strs Ohio (0.08%) and Retirement Systems of Alabama (0.07%). Company insiders that own Merck & Co., Inc. stock include Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks.
View institutional ownership trends for Merck & Co., Inc.
.

Which major investors are selling Merck & Co., Inc. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including Capital Wealth Planning LLC, Gateway Investment Advisers LLC, Schafer Cullen Capital Management Inc, New York State Teachers Retirement System, Hexavest Inc., Cullen Capital Management LLC, Cadinha & Co. LLC, and Retirement Systems of Alabama. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Frank Clyburn, Julie L Gerberding, Robert M Davis, Sanat Chattopadhyay, and Wendell P Weeks.
View insider buying and selling activity for Merck & Co., Inc.
or view top insider-selling stocks.

Which major investors are buying Merck & Co., Inc. stock?

MRK stock was acquired by a variety of institutional investors in the last quarter, including Alecta Pensionsforsakring Omsesidigt, Candriam Luxembourg S.C.A., KAMES CAPITAL plc, Radnor Capital Management LLC, Donaldson Capital Management LLC, Rhenman & Partners Asset Management AB, Sarasin & Partners LLP, and Kestra Advisory Services LLC.
View insider buying and selling activity for Merck & Co., Inc.
or or view top insider-buying stocks.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $80.25.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $203.04 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

What is Merck & Co., Inc.'s official website?

The official website for Merck & Co., Inc. is www.merck.com.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.